Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review

Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review

There is a high mortality rate associated with pancreatic cancer, and the incidence has been rising globally in recent decades. When patients are diagnosed, there is little chance that surgery will be beneficial. Systemic chemotherapy is the currently accepted treatment option for patients with meta...

Full description

Bibliographic Details
Main Authors: Yunpeng Wang, Bofang Wang, Lin Xiang, Junge Deng, Bo Xu, Puyi He, Weigao Pu, Haiyun Wang, Yong Fan, Hao Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
Anlotinib
PD-1 inhibitor
chemotherapy
metastatic pancreatic ductal adenocarcinoma
KRAS
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1016647/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1016647/full

Similar Items